Cargando…

Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report

BACKGROUND: Acute tubulointerstitial nephritis (ATIN) has been increasingly recognized as an important manifestation of kidney injury associated with the use of immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4). While the exact pathophysiology remains unknown, corticosteroids are the mainstay...

Descripción completa

Detalles Bibliográficos
Autores principales: Koda, Ryo, Watanabe, Hirofumi, Tsuchida, Masafumi, Iino, Noriaki, Suzuki, Kazuo, Hasegawa, Go, Imai, Naofumi, Narita, Ichiei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830324/
https://www.ncbi.nlm.nih.gov/pubmed/29486725
http://dx.doi.org/10.1186/s12882-018-0848-y
_version_ 1783302975126503424
author Koda, Ryo
Watanabe, Hirofumi
Tsuchida, Masafumi
Iino, Noriaki
Suzuki, Kazuo
Hasegawa, Go
Imai, Naofumi
Narita, Ichiei
author_facet Koda, Ryo
Watanabe, Hirofumi
Tsuchida, Masafumi
Iino, Noriaki
Suzuki, Kazuo
Hasegawa, Go
Imai, Naofumi
Narita, Ichiei
author_sort Koda, Ryo
collection PubMed
description BACKGROUND: Acute tubulointerstitial nephritis (ATIN) has been increasingly recognized as an important manifestation of kidney injury associated with the use of immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4). While the exact pathophysiology remains unknown, corticosteroids are the mainstay of management. CASE PRESENTATION: We describe a 67-year-old man with stage IV non-small-cell lung cancer who developed kidney injury during treatment with the anti-PD-1 antibody nivolumab. A kidney biopsy showed ATIN without granuloma formation. Considering their mechanism of action, immune checkpoint inhibitors can alter immunological tolerance to concomitant drugs that have been safely used for a long time. For more than 4 years before the initiation of nivolumab therapy, the patient had been receiving the proton pump inhibitor lansoprazole, known to cause drug-induced ATIN, without significant adverse events including kidney injury. He showed rapid improvement in kidney function in 3 days (creatinine decreased from 2.74 to 1.82 mg/dl) on discontinuation of lansoprazole. He then received 500 mg intravenous methylprednisolone for 3 days followed by 1 mg/kg/day oral prednisolone and his creatinine levels eventually stabilized around 1.7 mg/dl. Drug-induced lymphocyte stimulation test (DLST) for lansoprazole was positive. CONCLUSIONS: The rapid improvement of kidney function after discontinuation and DLST positivity indicate that lansoprazole contributed to the development of ATIN during nivolumab therapy. Considering the time course, it is plausible that nivolumab altered the long-lasting immunological tolerance against lansoprazole in this patient. To the best of our knowledge, this is the first case report of DLST positivity for a drug that had been used safely before the initiation of an immune checkpoint inhibitor. Although corticosteroid therapy is recommended, the recognition and discontinuation of concomitant drugs, especially those known to induce ATIN, is necessary for the management of kidney injury associated with anti-PD-1 therapy.
format Online
Article
Text
id pubmed-5830324
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58303242018-03-05 Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report Koda, Ryo Watanabe, Hirofumi Tsuchida, Masafumi Iino, Noriaki Suzuki, Kazuo Hasegawa, Go Imai, Naofumi Narita, Ichiei BMC Nephrol Case Report BACKGROUND: Acute tubulointerstitial nephritis (ATIN) has been increasingly recognized as an important manifestation of kidney injury associated with the use of immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4). While the exact pathophysiology remains unknown, corticosteroids are the mainstay of management. CASE PRESENTATION: We describe a 67-year-old man with stage IV non-small-cell lung cancer who developed kidney injury during treatment with the anti-PD-1 antibody nivolumab. A kidney biopsy showed ATIN without granuloma formation. Considering their mechanism of action, immune checkpoint inhibitors can alter immunological tolerance to concomitant drugs that have been safely used for a long time. For more than 4 years before the initiation of nivolumab therapy, the patient had been receiving the proton pump inhibitor lansoprazole, known to cause drug-induced ATIN, without significant adverse events including kidney injury. He showed rapid improvement in kidney function in 3 days (creatinine decreased from 2.74 to 1.82 mg/dl) on discontinuation of lansoprazole. He then received 500 mg intravenous methylprednisolone for 3 days followed by 1 mg/kg/day oral prednisolone and his creatinine levels eventually stabilized around 1.7 mg/dl. Drug-induced lymphocyte stimulation test (DLST) for lansoprazole was positive. CONCLUSIONS: The rapid improvement of kidney function after discontinuation and DLST positivity indicate that lansoprazole contributed to the development of ATIN during nivolumab therapy. Considering the time course, it is plausible that nivolumab altered the long-lasting immunological tolerance against lansoprazole in this patient. To the best of our knowledge, this is the first case report of DLST positivity for a drug that had been used safely before the initiation of an immune checkpoint inhibitor. Although corticosteroid therapy is recommended, the recognition and discontinuation of concomitant drugs, especially those known to induce ATIN, is necessary for the management of kidney injury associated with anti-PD-1 therapy. BioMed Central 2018-02-27 /pmc/articles/PMC5830324/ /pubmed/29486725 http://dx.doi.org/10.1186/s12882-018-0848-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Koda, Ryo
Watanabe, Hirofumi
Tsuchida, Masafumi
Iino, Noriaki
Suzuki, Kazuo
Hasegawa, Go
Imai, Naofumi
Narita, Ichiei
Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
title Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
title_full Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
title_fullStr Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
title_full_unstemmed Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
title_short Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
title_sort immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830324/
https://www.ncbi.nlm.nih.gov/pubmed/29486725
http://dx.doi.org/10.1186/s12882-018-0848-y
work_keys_str_mv AT kodaryo immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport
AT watanabehirofumi immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport
AT tsuchidamasafumi immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport
AT iinonoriaki immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport
AT suzukikazuo immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport
AT hasegawago immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport
AT imainaofumi immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport
AT naritaichiei immunecheckpointinhibitornivolumabassociatedkidneyinjuryandtheimportanceofrecognizingconcomitantmedicationsknowntocauseacutetubulointerstitialnephritisacasereport